RAPID Platform

JNANA HAS BUILT A NEXT GENERATION CHEMOPROTEOMIC PLATFORM TO DISCOVER SMALL MOLECULE MEDICINES FOR HARD-TO-DRUG TARGETS.

There is a vast opportunity in what has been considered the undruggable genome, with many well-validated protein targets that have been elusive to drug discovery using conventional tools.  

A new paradigm in chemoproteomics is putting hard-to-drug targets within reach. Jnana has built a proprietary chemoproteomic platform that enables an unprecedented interrogation of target proteins to reveal all druggable sites.

Novel therapeutics across a range of protein targets can become accessible with Jnana’s Reactive Affinity Probe Interaction Discovery (RAPID) platform which enables identification of druggable sites across the surface of a target protein in its native environment in live cells. By applying the RAPID platform, we can address a range of hard-to-drug targets, including SLC transporters, scaffold proteins, transcription factors, phosphatases, and helicases.

RAPID is a proprietary ligand discovery platform that identifies small molecule binders irrespective of the fold or function of the target protein, delivering high quality, chemical starting points for programs. RAPID is ideally suited for hard-to-drug targets including SLC transporters which are highly diverse based on structure and cellular location, often difficult to express and purify, are not readily amenable to biophysical methods, and may have no known ligands.

Because RAPID identifies small molecules based only on their ability to bind the protein, it provides an unbiased approach for tackling challenging targets. Binders are valuable due to their unexpected pharmacology, including effects on protein-protein interactions, post-translational modifications, sub-cellular localization, or half-life – in addition to canonical inhibition. (Schreiber, Israel J. Chem., 2019)

The RAPID platform is a ‘plug-and-play’ technology that is based on three core capabilities:

Jnana platform

 

 

Hard-to-drug targets with validated human biology remain elusive. Jnana is using our RAPID platform to advance drug-discovery programs in our internal pipeline and in collaborations with biopharma partners to systematically target these hard-to-drug targets and develop small molecule therapeutics in immunology, oncology, and metabolite dependent diseases.

Back to Top
 

This links to an external website. Merus is not responsible for any third party content.

Continue